Work

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

Year: 2017

Type: article

Study design: Clinical Trial

Source: Melanoma Research

DOI: 10.1097/cmr.0000000000000399

Authors: Jason Chesney, Sanjay Awasthi, Brendan Curti, Laura Hutchins, Gerald Linette, Pierre Triozzi, Marcus C.B. Tan, Russell E. Brown, John Nemunaitis, Eric Whitman, Christopher Windham, Jose Lutzky, Gerald F. Downey, Nicolas Batty, Thomas Amatruda

Institutions: University of Louisville, City Of Hope National Medical Center, City of Hope, Amgen (United States), Providence Portland Medical Center, University of Arkansas for Medical Sciences, Washington University in St. Louis, Cone Health, University of South Alabama, Ochsner Medical Center, Mary Crowley Cancer Research Center, Atlantic Health System, Mount Sinai Medical Center, Minnesota Oncology, Amgen (United Kingdom)

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W2769213797

FWCI: 3.09

Cites: 21

Cited by: 38

Related to: 10